Charles Link, MD profile page

Dr. Link currently serves as an Adjunct Professor at the Lankenau Institute for Medical Research (LIMR) where his work is primarily focused on mechanistic studies and clinical trials to evaluate Syncromune’s SYNC-T Therapy based therapeutic principles. Dr. Link has conducted research in DNA repair and focused on translational research to develop new cancer treatment approaches. He has designed and conducted clinical studies focused on cancer vaccine technology utilizing the alpha(1,3)galactosyl-epitope to activate the immune response. Prior to joining Syncromune, Dr. Link was the previous Founder, Chairman and Chief Executive Officer of NewLink Genetics, a clinical-stage company focused on the development of new immuno-oncology treatments. Dr. Link co-founded NewLink Genetics in 1999 with the idea of leveraging the body’s immune system to fight cancer. He also founded BioProtection Systems Corporaton and led the in-licensing of vaccine technologies for life threatening viral infections. Dr. Link is a highly sought after board member, most recently on the board of NovaScan Corporation in Chicago, QSAM Bioscience (sold to Telix Pharmaceuticals in 2024) and Viewpoint Molecular Targeting, Inc in Iowa (which merged with a NASDAQ company in 2023 to create Perspective Therapeutics). Dr. Link immensely enjoys spending time with his wife, four children and two grandchildren.